These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
285 related articles for article (PubMed ID: 33724703)
1. Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade. Buchbinder EI; Weirather JL; Manos M; Quattrochi BJ; Sholl LM; Brennick RC; Bowling P; Bailey N; Magarace L; Ott PA; Haq R; Izar B; Giobbie-Hurder A; Hodi FS Cancer Med; 2021 Apr; 10(8):2627-2635. PubMed ID: 33724703 [TBL] [Abstract][Full Text] [Related]
2. Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma. Hintzsche JD; Gorden NT; Amato CM; Kim J; Wuensch KE; Robinson SE; Applegate AJ; Couts KL; Medina TM; Wells KR; Wisell JA; McCarter MD; Box NF; Shellman YG; Gonzalez RC; Lewis KD; Tentler JJ; Tan AC; Robinson WA Melanoma Res; 2017 Jun; 27(3):189-199. PubMed ID: 28296713 [TBL] [Abstract][Full Text] [Related]
3. The mutational landscape of mucosal melanoma. Nassar KW; Tan AC Semin Cancer Biol; 2020 Apr; 61():139-148. PubMed ID: 31655118 [TBL] [Abstract][Full Text] [Related]
6. Predominance of triple wild-type and IGF2R mutations in mucosal melanomas. Iida Y; Salomon MP; Hata K; Tran K; Ohe S; Griffiths CF; Hsu SC; Nelson N; Hoon DSB BMC Cancer; 2018 Oct; 18(1):1054. PubMed ID: 30373548 [TBL] [Abstract][Full Text] [Related]
7. Clinical Outcomes of Immune Checkpoint Blocker Therapy for Malignant Melanoma in Korean Patients: Potential Clinical Implications for a Combination Strategy Involving Radiotherapy. Lee J; Chang JS; Roh MR; Jung M; Lee CK; Oh BH; Chung KY; Koom WS; Shin SJ Cancer Res Treat; 2020 Jul; 52(3):730-738. PubMed ID: 32054150 [TBL] [Abstract][Full Text] [Related]
9. Immunogenic cell death signatures from on-treatment tumor specimens predict immune checkpoint therapy response in metastatic melanoma. Zeng H; Jiang Q; Zhang R; Zhuang Z; Wu J; Li Y; Fang Y Sci Rep; 2024 Oct; 14(1):22872. PubMed ID: 39358546 [TBL] [Abstract][Full Text] [Related]
10. Transient activation of tumoral DNA damage tolerance pathway coupled with immune checkpoint blockade exerts durable tumor regression in mouse melanoma. Zhuo M; Gorgun FM; Tyler DS; Englander EW Pigment Cell Melanoma Res; 2021 May; 34(3):605-617. PubMed ID: 33124186 [TBL] [Abstract][Full Text] [Related]
11. Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma. Jiang J; Ding Y; Wu M; Chen Y; Lyu X; Lu J; Wang H; Teng L Cancer Med; 2020 Nov; 9(22):8498-8518. PubMed ID: 32969604 [TBL] [Abstract][Full Text] [Related]
12. Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better. Zheng M J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101940 [TBL] [Abstract][Full Text] [Related]
13. Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma. Loo K; Smithy JW; Postow MA; Betof Warner A Front Immunol; 2021; 12():810388. PubMed ID: 35087529 [TBL] [Abstract][Full Text] [Related]
14. Somatic mutations in DCC are associated with genomic instability and favourable outcomes in melanoma patients treated with immune checkpoint inhibitors. Li Y; Wang Q; Chen Y; Zhao L Br J Cancer; 2022 Nov; 127(8):1411-1423. PubMed ID: 35871235 [TBL] [Abstract][Full Text] [Related]
15. H3K27me3 and EZH2 expression in melanoma: relevance for melanoma progression and response to immune checkpoint blockade. Hoffmann F; Niebel D; Aymans P; Ferring-Schmitt S; Dietrich D; Landsberg J Clin Epigenetics; 2020 Feb; 12(1):24. PubMed ID: 32041674 [TBL] [Abstract][Full Text] [Related]
16. HLA class II immunogenic mutation burden predicts response to immune checkpoint blockade. Shao XM; Huang J; Niknafs N; Balan A; Cherry C; White J; Velculescu VE; Anagnostou V; Karchin R Ann Oncol; 2022 Jul; 33(7):728-738. PubMed ID: 35339648 [TBL] [Abstract][Full Text] [Related]
18. Biological Pathway-Derived TMB Robustly Predicts the Outcome of Immune Checkpoint Blockade Therapy. Miao YR; Liu CJ; Hu H; Yang M; Guo AY Cells; 2022 Sep; 11(18):. PubMed ID: 36139377 [TBL] [Abstract][Full Text] [Related]
19. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition. Kim HS; Jung M; Kang HN; Kim H; Park CW; Kim SM; Shin SJ; Kim SH; Kim SG; Kim EK; Yun MR; Zheng Z; Chung KY; Greenbowe J; Ali SM; Kim TM; Cho BC Oncogene; 2017 Jun; 36(23):3334-3345. PubMed ID: 28092667 [TBL] [Abstract][Full Text] [Related]